PML problems loom for Rituxan.
Malorye
M
Allison
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects; D004345:Drug Industry; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D011358:Product Surveillance, Postmarketing; D000069283:Rituximab; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab